KALA BIO shares surge 18.20% after-hours following $10.6 million debt settlement announcement.

KALA BIO, Inc. (KALA) surged 18.20% in after-hours trading following the announcement that it settled approximately $10.6 million of debt. This development, reported by GlobeNewswire, signals improved financial flexibility and reduces immediate liquidity pressures, likely boosting investor confidence. The move aligns with the company’s recent capital-raising efforts, including a $10 million registered direct offering in February 2025, though older news of a failed clinical trial and an 88% stock decline in March 2025 remains contextually relevant. The after-hours rally reflects optimism over the debt resolution and potential operational stability.